A NEW ERA FOR CANCER THERAPY
Company Overview
At OncoTEX, we’re on a mission to treat cancer effectively, without the prohibitive side effects we know today. We are addressing an urgent major unmet clinical need by transforming cancer therapy with TEX Core, an oncology drug platform that can create a new suite of life-changing cancer therapeutics.
OncoTEX is developing TEX Core, a world-first oncology drug platform designed to create innovative therapies capable of overcoming multiple limitations often associated with current cancer therapeutics, including the predominant platinum-based resistance. OxaliTEX is the first clinical candidate developed from the TEX Core platform for the treatment of platinum-resistant ovarian cancer. TEX Core is designed to target tumor cells by overcoming challenges associated with the current platinum-based standards-of-care (SOC).
Tex Core
A world first platform, TEX Core primarily uses texaphyrin as the basis for a series of conjugates designed to treat drug-sensitive and drug-resistant solid tumors.
TEX Core-developed compounds are designed to be tumor localizing, well-tolerated, MRI-detectable and efficacious in multiple solid tumors, including cancer cells that fail to respond to current therapies.
Location
3800 N Lamar Blvd, Austin, Texas 78756
Get in Touch with Us
Want to learn more about OncoTEX or have a question about our approach? Use the contact form and let’s start a conversation.